New drugs in development for the treatment of endometriosis
Abstract
Endometriosis is a common and enigmatic disease causing pelvic pain and infertility. Current treatment is mainly based on the use of surgery and ovarian suppressive agents. There is in particular the need for new therapeutic options able to allow a normal menstrual cycle to occur and also consent pregnancy. In the present review, we aimed to give a concise and practical overview in order to allow the clinician to clearly understand the level of development of these drugs. We have presented only treatments supported by in vivo researches with a special attention to studies in humans. Results show appealing new possibilities are emerging from agents counteracting the endometriosis-associated inflammation. Recent data also suggests that there is still the opportunity to refine the use of already available agents.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Hormone therapies that lower estradiol or act on progesterone reduce pain in women with endometriosis.
“The fact that hormonal treatments that reduce estradiol levels or influence progesterone alleviate pain in women with endometriosis supports the conclusion that estradiol contributes to pain symptoms and that progestogens may contribute to decreased symptoms (Fedele et al., 2008;Huang, 2008;Aghajanova et al., 2009).”
From Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications (2011) · cites this paper as Fedele et al., 2008
The citation lists haven’t been fetched yet
References 133 · Cited by 30
- Authors
- Fedele, L., Somigliana, E., Frontino, G., Benaglia, L., & Vigano, P.
- Affiliations
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Università degli Studi di Milano, Via Commenda 12, 20122 Milan, Italy
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2008-07-10
- Volume
- 17
- Issue
- 8
- Pages
- 1187-1202
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2048751813
- Cited by
- 30
- References
- 133
- Citations by year
- 2022: 1 · 2021: 2 · 2019: 1 · 2018: 1 · 2016: 2 · 2015: 2 · 2013: 1 · 2012: 2
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- endometriosis, drug development, infertility, pelvic pain, pregnancy, menstrual cycle, investigational drugs
- MeSH terms
- Animals, Anti-Inflammatory Agents, Endometriosis, Female, Hormone Antagonists, Humans, Receptors, Estrogen, Receptors, Progesterone, Tumor Necrosis Factor-alpha, Drug Design, Treatment Outcome, Angiogenesis Inhibitors, Aromatase Inhibitors, PPAR gamma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
